Discrepancies between Canadian cancer research funding and site-specific cancer burden
Authors: A. C. Coronado, C. Finley, K. Badovinac, J. Han, J. Niu, and R. Rahal
Background Cancer research is essential in evaluating the safety and effectiveness of emerging cancer treatments, which in turn can lead to ground-breaking advancements in cancer care. Given limited research funding, allocating resources in alignment with societal burden is essential. However, evidence shows that such alignment does not typically occur. The objective of the present study was to provide an updated overview of site-specific cancer research investment in Canada and to explore potential discrepancies between the site-specific burden and the level of research investment. Methods The 10 cancer sites with the highest mortality in 2015-which included brain, female breast, colorectal, leukemia, lung, non-Hodgkin lymphoma, ovary, pancreas, prostate, and uterus-were selected for the analysis. Information about site-specific research investment and cancer burden (raw incidence and mortality) was obtained from the Canadian Cancer Research Survey and Statistics Canada’s cansim (the Canadian Socio-Economic Information Management System) respectively. The ratio of site-specific research investment to site-specific burden was used as an indicator of overfunding (ratio > 1) or underfunding (ratio < 1). Results The 3 cancer sites with the highest research investments were leukemia, prostate, and breast, which together represented 51.3% of 2015 cancer research funding. Conversely, the 3 cancer sites with the lowest investments were uterus, pancreas, and ovary, which together represented 7.8% of 2015 research funding. Relative to site-specific cancer burden, the lung, uterus, and colorectal sites were consistently the most underfunded. Conclusions Observed discrepancies between cancer burden and research investment indicate that some cancer sites (such as lung, colorectal, and uterus) seem to be underfunded when site-specific incidence and mortality are taken into consideration.
Please note that abstracts only appear in the language of the publication and might not have a translation.
Michelle Le, Feras M. Ghazawi, Akram Alakel, Elena Netchiporouk, Elham Rahme, Andrei Zubarev, Mathieu Powell, Linda Moreau, Osama Roshdy, Steven J. Glassman, Denis Sasseville, Gizelle Popradi, and Ivan V. Litvinov (2019).
Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada
Current Oncology , e473-e481
Emily V. Walker, J. Ross, Y. Yuan, T. R. Smith, and F. G. Davis (2019).
Brain cancer survival in Canada 1996-2008: Effects of sociodemographic characteristics
Current Oncology , 292-299
A. Blair, L. Gauvin, S. Ouédraogo, and G. Datta. (2019).
Area-level income and colorectal cancer screening among urban-dwelling Canadians: Evidence to guide future surveillance
Current Oncology , 128-137
Y. Yuan, J. Ross, Q. Shi, and F. G. Davis (2017).
Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008
Current Oncology , 341-347
Laetitia Amar, Michelle Le, Feras M. Ghazawi, Elham Rahme, Amanda Segal, Elena Netchiporouk, Gizelle Popradi, Linda Moreau, Osama Roshdy, Denis Sasseville, and Ivan Litvinov (2019).
Prevalence of human T cell lymphotropic virus 1 infection in Canada
Current Oncology , e3-e5
Simon F. Roy, Feras M. Ghazawi, Michelle Le, François Lagacé, Catherine F. Roy, Elham Rahme, Evgeny Savin, Andrei Zubarev, Denis Sasseville, Gizelle Popradi, and Ivan V. Litvinov (2020).
Epidemiology of adult and pediatric Burkitt Lymphoma in Canada: Sequelae of the HIV epidemic
Current Oncology , 83-89
J. Tung, C. E. Politis, J. Chadder, J. Han, J. Niu, S. Fung, R. Rahal, and C. C. Earle (2018).
The north-south and east-west gradient in colorectal cancer risk: A look at the distribution of modifiable risk factors and incidence across Canada
Current Oncology , 231-235